NYSEFinancialsBanks - DiversifiedSnapshot 2026-07-31
Reading UBS? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Financials is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — earnings per share reach about $3.31: EPS $3.34 vs ~$3.31.
View ThesisModerate volatility — typically moves about 1% a day.
View RiskUBS's growth depends on strong financial performance and sector support. Total revenue reached about $42.8 billion, slightly above the target of $41.8 billion. UBS trades at a premium compared to peers, which implies a price about 15% below where it currently trades. The primary risk is that sector bellwethers like JPM and BAC start missing earnings. Peer multiples imply a price about 15% below where it trades; this read is provisional.
Trailing returns as of 2026-07-31. UBS is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 3 analysts currently covering UBS (as of Jul 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A consensus fair price across 1 valuation methods, at three horizons. As of 2026-08-01. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Financials (broad) — fair value, gap to price, and forward P/E.
The buyback indicates strategic recovery from Credit Suisse acquisition.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-31. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Earnings call provides insights into future performance expectations.
Upgrade to Neutral suggests improved outlook for UBS.
Positive forecast on China trade supports growth outlook.
Share repurchase plan boosts investor confidence and stock price.
Record profits and strategic growth support valuation.
Strong profit and revenue growth supports investment thesis.
Positive rating upgrade supports UBS's valuation strategy.
